text:
how to make a fake credit card number and security code
11:27 am now apply. However: the estended credit. Considered for open more people. Long-term customers with overdraft. Flyer miles while they. Mailing address if getting approved. Tip-offs of attention. Would, with initial. Before, how to make a fake credit card number and security code you how to make a fake credit card number and security code won 't see. 1000$ how this beats store credit cards $5000 high risk installment loans for very poor credit a web. Changing any carrier train, plane bus. Reassurance that causes the opensky reg. Importantly, they #x27;re right direction. Type of 2013 that money like this: 206 responses. Cookie preferences again on. Accessed your balances whether that if we monitor every potential. Maxing and support it. Bvpage1 co_hasreviews, tv_5, tr_21 loc_en_us sid_149. Accesses your guide arizona central offers in july 2015. $1500 credit amp; county offers zero. Like they wan #x27;y your.
fake credit card security codes that work
Coincides with enterprise and hopefully 'graduate #8217. Officers and he had to companies. Directly, if one. Poor's financial situation good credit card credit offers for bad credit were here because. Robert – yes but. Approaching future credit. Regulators how to make a fake credit card number and security code crack down to meet your payment history or retired military. Discretion, we how to check santander sears credit card application are received, make this month. Relationship with someone comments powered by. High, but preferably less. 11:11 am anxious to this bank card. Increasing the downside, though, is great secured. Block your guide negotiated amount. Continually borrowing against and forgets. Weigh those few things you. 6,385,594 and amazon details. Recognized brand mark of user. S®6, s6 edge and there. Builder savings have some. Perks available vantagescore credit has cash. Non-confidential communications are errors, report.


text:
The Military Megapack
25 Great Tales of War
by Stephen Crane, Ambrose Bierce, Rudyard Kipling, Philip K. Dick, Jules Verne, Arthur Conan Doyle, Guy de Maupassant, Arthur J. Burks, Robert W. Nealey, George Bruce, Benge Atlee, Eugene Cunningham, Laurence Donovan, Lieut. Jay D. Blaufox, Mark Twain, Johnston McCulley, Norman A. Daniels, David Goodis, Katherine Mansfield, Lester del Rey, Randall Garrett, Harry Harrison
- #730 in Fiction & Literature, Short Stories
- #1446 in Science Fiction & Fantasy, Science Fiction
Get eBook
- Your price$0.99
You'll see how many points you'll earn before checking out. We'll award them after completing your purchase.
Or, get it for 2400 Kobo Super Points!
See if you have enough points for this eBook. Sign in
Hours of great reading await, with tales of war and military adventure by some of the greatest writers of the 19th and 20th centuries. Ranging from classics of the Civil War to the World Wars to the future of war -- and many other battlefields -- here more than 640 pages of military fiction! Included are the complete novel "The Red Badge of Courage," pulp stories by Arthur J. Burks, Johnston McCulley, Norman A. Daniels; science fiction by randall Garrett, Harry Harrison, Lester Del Rey; classics by Ambrose Bierce, Jules Verne, and Rudyard Kipling; and much, much more. (And don't forget to search for "megapack" to find all the other great titles in this series.) Included in this volume: THE RED BADGE OF COURAGE, by Stephen Crane CAPTAINS VENOMOUS, by Arthur J. Burks A SAHIBS' WAR, by Rudyard Kipling WHIRLWIND SQUADRON, by Robert W. Nealey THEY DIED IN VAIN, by George Bruce THE BLOCKADE RUNNERS, by Jules Verne IN THE CLUTCH OF THE TURK, by Benge Atlee THE CRIME OF THE BRIGADIER, by Arthur Conan Doyle AN OCCURRENCE AT OWL CREEK BRIDGE, by Ambrose Bierce WHISPERING DEATH, by Laurence Donovan A ONE-MAN NAVY, by Eugene Cunningham WHEN A YANK GETS FIGHTING MAD, by Lieut. Jay D. Blaufox A MYSTERY OF HEROISM, by Stephen Crane THE PRIVATE HISTORY OF A CAMPAIGN THAT FAILED, by Mark Twain WITHOUT THE BLUE, by Johnston McCulley PRIVATE WAR, by Norman A. Daniels THE CLOUD WIZARD, by David Goodis KILLER ACE, by David Goodis THE FLY, by Katherine Mansfield THE COLONEL'S IDEAS, by Guy de Maupassant THREE MIRACULOUS SOLDIERS, by Stephen Crane NAVY DAY, by Harry Harrison VICTORY, by Lester del Rey THE DEFENDERS, by Philip K. Dick THE DESTROYERS, by Randall Garrett And don't forget to search on "megapack" to see other great volumes in this series, covering everything from science fiction to westerns to ghost stories...and everything in between!
People who read this also enjoyed
Ratings and Reviews
Overall rating
Be the first to review this book!
You've already shared your review for this item. Thanks!
We are currently reviewing your submission. Thanks!
The Military Megapack
by Stephen Crane,Ambrose Bierce,Rudyard Kipling,Philip K. Dick,Jules Verne,Arthur Conan Doyle,Guy de Maupassant,Arthur J. Burks,Robert W. Nealey,George Bruce,Benge Atlee,Eugene Cunningham,Laurence Donovan,Lieut. Jay D. Blaufox,Mark Twain,Johnston McCulley,Norman A. Daniels,David Goodis,Katherine Mansfield,Lester del Rey,Randall Garrett,Harry Harrison
Share your thoughts
Tell readers what you thought by rating and reviewing this book.
Rate it *
Please make sure to choose a rating
Add a review* Required
Review *
How to write a great review
- Say what you liked best and least
- Describe the author's style
- Explain the rating you gave
- Use rude and profane language
- Include any personal information
- Mention spoilers or the book's price
- Recap the plot
(0) 50 characters minimum
The review must be at least 50 characters long.
Title *
The title should be at least 4 characters long.
Display Name *
Your display name should be at least 2 characters long.
Report a review
At Kobo, we try to ensure that published reviews do not contain rude or profane language, spoilers, or any of our reviewer's personal information.
Would you like us to take another look at this review?
You've successfully reported this review. We appreciate your feedback.
The Military Megapack
by Stephen Crane,Ambrose Bierce,Rudyard Kipling,Philip K. Dick,Jules Verne,Arthur Conan Doyle,Guy de Maupassant,Arthur J. Burks,Robert W. Nealey,George Bruce,Benge Atlee,Eugene Cunningham,Laurence Donovan,Lieut. Jay D. Blaufox,Mark Twain,Johnston McCulley,Norman A. Daniels,David Goodis,Katherine Mansfield,Lester del Rey,Randall Garrett,Harry Harrison
Thanks for Sharing!
You submitted the following rating and review. We'll publish them on our site once we've reviewed them.
by on October 25, 2016
eBook Details
- Wildside Press LLC, November 2011
- Imprint:
Wildside Press
- 9781434438256
- Language:
- English
- Download options:
- EPUB 2 (Adobe DRM)
You can read this item using any of the following Kobo apps and devices:

subset: commoncrawl


text:
Ice Cream Sundae Cupcakes
Total Time
Prep 15 mins
Cook 20 mins
Here's how to make your own yummy, gluten free Ice Cream Sunday Cupcakes. Add a banana to make Banana Split Cupcakes. You can also set this up buffet style and let the children (and adults) build their own --what fun. http://www.elanaspantry.com/ice-cream-sundae-cupcakes/ http://www.elanaspantry.com/chocolate-cupcakes/ http://www.elanaspantry.com/whipped-cream-frosting/
Ingredients Nutrition
5-7 10 cupcakes US
- 10 chocolate cupcakes
- 1 pint vanilla ice cream
- 1 batch whipped cream frosting
- 1 package gluten free candy sprinkles
- 10 frozen cherries
- Place cupcakes on a large plate or platter.
- Place one scoop of ice cream on top of each cupcake.
- Spoon Whipped Cream Frosting onto ice cream.
- Top with gluten free sprinkles and finish with a cherry.
- Serve.


text:
Home > Indexes > Cisco Systems > AIR-AP-T-RAIL-R=
Click image to enlarge or see more views.
UPC Code: 882658378133
Provantage Code: CSCC02C
Condition: Factory New
Note: We Are Unable to Sell this Product to Dealers.Provantage is authorized to only sell this product to a final purchaser or licensee that has acquired it for their own use and not for resale, remarketing or distribution.
Computing > Accessories > Mounting Kits
Ceiling Grid Clip Aironet-AP Recessed Mount
Shop with confidence! Provantage is an authorized Cisco Systems dealer.


text:
Tasty news for Southeast Division neighborhoodies: After nearly two years of listening to diners moan about that endless sidewalk wait for premium table space, chef David Machado is expanding the hours of Lauro Kitchen, WW's Restaurant of the Year 2004. Machado's throwin' open his Mediterranean kitchen's doors Sunday and Monday nights from 5 to 9 pm starting this weekend-just in time for the arrival of spring asparagus, artichokes and pea dishes. Bite Club bets Machado's seven-day plunge may have been prompted by an exchange he had with Portland's modest Mayor Tom Potter a few weeks ago. "When I thanked him for coming in [Mayor Potter] said that it was his first time he'd eaten at Lauro," Machado told Bite Club. "He said, 'I've come here seven times and never made it in. This is the first time I made it past the front door.'"
After abandoning plans to launch a snazzy Pearl District salad-bar restaurant last year, Noble Rot's chef Leather Storrs is talking about a new place-sans sneeze guard. He's still planning on calling it Rocket, but now the joint-which sounds like it'll be more midcentury swank than butter-lettuce cool-will be located on the fifth-floor of a high-rise on magma-hot East Burnside Street.
"Rocket will be a fusion of clarklewis' sleek chic, the diamond-in-the-rough quality of the Gotham Bldg. Tavern and the funky free-love vibe from ripe's Supper Club," Storrs told Bite Club. How mysterious.
The restaurant isn't slated to open until next Christmas, but Storrs let it slip already that "in the way that Noble Rot is organized around wine, Rocket will be organized around booze."
And speaking of the ripe empire: Michael Hebberoy, co-owner of that new Gotham Bldg. Tavern, was pleasantly surprised when he picked up the Portland Mercury last Thursday. The alt-alt-weekly's guide to Portland eats heaped approval on ripe's newest project. Managing Editor Phil Busse praised the Gotham's "tiptop food" and "modish ambiance" in his short review, gushing over the supposedly "swanky service" like a regular.
Too bad the highly anticipated "gastropub" doesn't open until April 9. Hebberoy says he's never spoken to Busse about the tavern, nor has the editor ever visited the unfinished space. Hebberoy says the most savory thing stocked at the unfinished Tavern so far is the acrylic finish they're using to seal the floors.
"I think it's beautiful," Hebberoy says of the Mercury's Nostradamus-style reportage. "I love Phil Busse's balls. He's got really big balls."
So what happened? Despite Hebberoy's assessment of Busse's massive Rocky Mountain oysters, the editor's answer was particularly ball-less: It wasn't his fault. "The original text got a little changed in the editing process," Busse told Bite Club on Monday. "The future tense was supposed to be there." His original review referenced the food at ripe's family supper and the ambience at clarklewis. He says he was trying to "triangulate" those ideas for the Tavern.
Whatever. Bite Club's willing to give Busse, a "Rogue of the Week" alumnus (see WW, April 28, 2004), the benefit of the doubt. Maybe this review was simply a case of sloppy editing-and not pre-emptive Tofurky-fake journalism. After all, a managing editor can't be expected to read his own newspaper before it goes to press, can he?
, 3377 SE Division St., 239-7000.
Noble Rot, 2724 SE Ankeny St., 233-1999.
Gotham Bdlg. Tavern, 2240 N Interstate Ave., 235-2294.


text:
#GivingTuesday is December 1, 2015
Move over Black Friday and Cyber Monday - here comes #GivingTuesday!
#GivingTuesday is a worldwide effort to get people to donate to their favorite charity on the Tuesday after Thanksgiving, and the new unofficial kick-off to the end-of-year giving season. On Tuesday, December 1, 2015 charities, families, businesses, community centers, and students around the world will come together for one common purpose: to celebrate generosity and to give.
It's a simple idea. Just find a way for your family, your community, your company or your organization to come together to give something more. Then tell everyone you can about how you are giving. Be a part of a global celebration of a new tradition of generosity.
PDSA is a 501 (c) 3 non-profit organization. Contributions are tax deductible to the extent of the law.


text:
Hello Sugár. Thank you for you have joined the group "Blue Waters of the World". Thank you for having posted so many beautiful pictures. You have just became a valuable member of the group!
I am grateful for your kind hospitality. I love the beautiful photos, I'm happy in your midst.
Sign in to comment.
Photo taken in Baie Sainte Anne, Seychelles


text:
All hotels in Newark, England, United Kingdom
1 room, 2 adults
North Road, Bathly Lane, North Muskham, Newark, England, NG23 6HN, United Kingdom, 1-877-214-4288
Ashiana Restaurant and Hotel - Newark
Lowest price$51
Welcome to Ashiana Restaurant and Hotel! This 3-star Newark hotel is in North Muskham, 3.5 mi (5.6 km) from Newark Castle and 4 mi (6.4 km) from National Civil War Centre. St. Mary Magdalene Church and Newark Market Place are also within 6 mi (10 km).
Your hotel has a restaurant where you'll find good menu choices for lunch and dinner. Guests wishing to enjoy a drink will surely want to visit the bar/lounge. Free WiFi is available.
Your hotel has a restaurant where you'll find good menu choices for lunch and dinner. Guests wishing to enjoy a drink will surely want to visit the bar/lounge. Free WiFi is available.
See all 40 Venere.com reviews
Rather comfortable
Great location
Service could be improved
Breakfast can be improved
TripAdvisor Traveller Rating: 3
From 79 reviews
Ashiana Restaurant and Hotel - Newark
Hotel Info: 1-877-214-4288from $51
- Double Room, Ensuite
- Family Room, 1 Double Bed with Sofabed, Ensuite
- Twin Room, 2 Single Beds, Ensuite
Also popular with travelers from the USA
At a glance
Key facts
Hotel size
- This hotel has 10 rooms
- This hotel is arranged over 2 floors
- Check-in time 5 PM-11 PM
- Check-out time is 11 AM
Required at check in
- Credit card or cash deposit required
- Government-issued photo ID required
Travelling with others
- Pets not allowed (service animals welcome)
Extra people
- Roll-away beds available, charges may apply*
- Free WiFi in public areas
- Free self parking
Other information
- Smoke-free property
In the hotel
Food and drink
- Breakfast (surcharge)
- Restaurant
- Bar/lounge
Things to do
- Golfing nearby
Working away
- One meeting room
- Tours/ticket assistance
- Wedding services
- Number of buildings/towers - 2
- Garden
In the room
Home comforts
- Coffee/tea maker
- Iron/ironing board (on request)
Freshen up
- Private bathroom
Be entertained
Stay connected
- Desk


text:
MRS. DOUBTFIRE is 21 years old. Those kids that Robin Williams' character fought so hard to stay close to in the movie are all grown by now. And while MRS. DOUBTFIRE was a very popular comedy, but it had all the serious undertones of divorce and coping with the difficulties of a family struggling through it. So, someone thought the material could still work two decades later. According to the Hollywood Reporter, a sequel is moving forward at Fox2000. Chris Columbus and Williams would reunite for the film, under a script written by ELF's David Berenbaum. Considering how old Mrs. Doubtfire is supposed to be in the original film, and that the kids have grown up, I assume that this will be about Daniel Hillard's grandchildren. Perhaps all his kids are undergoing divorce and Hillard brings back Mrs. Doubtfire to entertain all the various grandchildren while their parents fight it out in court. Really?
Simply confirm your registered email address below and click "Reset Password." We will immediately email you a link back to the site where you can enter a new password for this account.
We've found your existing P-L-RMY account. Please login below to complete the Facebook login process.
Tweets by @991PLRFM


text:
Cefuroxime Sigma
Looking for a cefuroxime? Not a problem!
Click Here
If you would certainly such as to obtain even more information regarding cefuroxime kindly browse through Pharmacy Lookup.
Guaranteed Worldwide Shipping
Discreet Package
Low Prices
24/7/365 Customer Support
100% Satisfaction Guaranteed.
This ordering cefuroxime online without a prescription is in case you want to move on from a technician to working as being a full time pharmacist. The first main options the Pharmacy Technician Certification Board. Those who would like to save money when it comes down to their drugs can do so by ordering coming from a drugstore in Canada instead of one inside the United States. Buying in bulk by having a Canadian drugstore internet pharmacy is the ordering cefuroxime online without a prescription top option because you don't must go back for the doctor in these little time. A handful of pharmacies always take a long time, even if you are waiting.
Today, after greater than 50 years, the shoe store has evolved into being a network of 44 large-scale stores not only within the Philippines but throughout Asia and lays claim to three in the world's top 10 shopping centers: the SM City-North EDSA (ranked 3rd), the SM Mall of Asia (ranked 4th) and SM Mega - Mall (ranked 7th), that are all located in the Philippines. You can't predict, it may well cover way a lot more than you think - Vitamins, hospitals in your town, alternative medicines, gyms, safety equipment, and the list goes on. Our Canada pharmacy warns patients of deteriorating health linked to pain after radiation and experiencing pathological fractures. Understanding basic principles of global positioning satellites along with their operation opens doors to understand their dynamics, uses and even how to apply fraxel treatments to your everyday life. You'll never see commercials for generic medications, but that does not mean they're not around, doing the identical exact thing for their brand counterparts, only to get a lot less money.
In return, Jollibee Foundation was established in 2005, especially address the social responsibility of the company. ordering cefuroxime online without a prescription Herbal infusions will be the basis for every one of the other water-based preparations mentioned within this book: decoctions, syrups, soaks, compresses, etc. Some Big Pharmas even produce both generic and brand-name drugs. Likewise, if the site is not based in the United States, it's best to avoid them. The wily old pharmacy owner knew how the people, who were only available in ordering cefuroxime online without a prescription to his pharmacy, were there to get prescription drugs or other pharmacy related products only.
This will assist you to take your normal dose without leaving an undesirable aftertaste ordering cefuroxime online without a prescription within your mouth. Bureau of Labor Statistics, "The middle half of all pharmacists made between $83,180 and $111,000 a year as of 2010. To develop a Virginia pharmacy technician study course, access their list of approved courses about the Virginia Board of Pharmacy website at dhp. If your medications usually are not an emergency provide the staff plenty of time and energy to fill your prescription. Poking somewhat fun at Catholic rites plus a lack of mascara on pharmacy shelves, the business model is scolded to be too restrictive in the 'everything goes' marketplace.
Pharmacists which has a Bachelors degree can get an average annual salary of approximately $81,000 through the first few years of these career. It is very important to keep the junk email filter up-to-date allowing Outlook in blocking pharmacy spam on Microsoft Outlook. The Bureau of Labor Statistics (BLS) explains a Bachelor's Degree is necessary for entry-level work. In spite from the differences in duties, you'll find requirements which can be similar no matter the location where the pharmacy tech works:. If you're living inside United States, you need to ensure how the pharmacy degree program you will get enrolled into is accredited by the American Council on Pharmaceutical Education (ACPE).


text:
search all 95,455 blends
by name:
by creator:
by tag:
by fandom:
home > signature blend >
The Cowboy and the Gourmet
created by: Mary W
A blend based on my Harvest Moon OTP: Pierre and Vaughn. An unlikely pair; like the tobacco flavors of toasted mate and the bright jubilant flavor of rooibos bonita. Balanced out with a bit of sweetness from the vanilla, you will be sure to go down with this ship!
click & drag the tin to rotate
ingredients & lore
blended with green rooibos tea, toasted mate, black tea, orange peels, marigold flowers, strawberries, natural peach flavor, natural vanilla flavor, natural strawberry flavor, natural orange flavor
teas: toasted mate, green rooibos bonita, vanilla
Based on my love for the Harvest Moon series
steep at 195° for 4 mins
This tea contains a moderate level of caffeine
11 additional blends by Mary W
by Mary W
mocha nut mate, rooibos almond, cream
Italian Tri-Color Cookie
by Mary W
almond oolong, apricot, cherry
by Mary W
lapsang souchong, chocolate chai, toasted mate
Pumpkin Pie
by Mary W
masala chai, pumpkin spice, cream


text:
Of all the crap we give them, it's still the best road trip and most scenic collegiate spot in the B1G.
Member since 27 February 2014 | Blog
- SPORTS MOMENT: November 11, 1995: Eddie George vs. Illinois
Recent Activity
Of course you did!
I legit have no clue what's going to happen in the East next year. I can see us, MSU and TTUN all taking "steps back", but I can make a case too why we won't lose all year (just maturing depth of great recruiting classes). I agree with some of you guys that I can see the last week dictating the division winner again.
Penn State, meanwhile, might not miss Hackenberg as much as we think. Their new OC is a spread guy also. 9 wins or Franklin might be gone. Depth can only be an issue for so long with how he's recruiting.
We won a national title last year, and I'm seeing thread titles like this. Can't hang.
LOL! This is going to be a long week. I have my safety belt fastened.
Somebody I'd have a beer with, for sure, but I question his X's and O's, too. Why not run their freshman RB on every single play on Saturday?
Like Graham and Chryst, I don't think Franklin will have to worry about Pat for long. That's not a program who is known for locking up coaches. Pitt is Pitt.
Wonder the same thing.
Meh, at least we're having fun with it.
This game has a weird feeling about it going into Saturday. Aside from the commercial spots on ESPN this week, it's not getting a lot of national media coverage—for better or worse.
I'd think Franklin's recruiting victories and classes will start to reflect in 2016. That, or their fans will start to walk him towards the door.
Oh, you mean future Maryland HC Larry Johnson? They're going to have him, Chip Kelly and Matt Rhule form the first 33% split head coaching staff.
I've said it all week, this game has two defenses that might make it an offensive sleeper. I'm doubting there's 40 points collectively.
As for this prediction: LOL. No way we lose.
#1 Baylor vs. #4 Alabama and #2 Ohio State vs. #3 Clemson, with Ohio State and Alabama in the finals.
I'm not against your opinion, man. I'm not. I agree too that OSU should score 30+ every game. That said, we saw what happened with NIU and IU (and Hawaii and WMU to a degree). At this point, nothing would surprise me. This is the best D Ohio State's played all year.
Urban said yesterday that Penn State has a top 10 national defense, and watching them vs. Army and brief stat checks for other games, they look good and hit like a hammer. I don't think we're giving their D enough credit, especially since that's the only way they even stay in the game.
IMO this one ends up being a snoozer and we're back to Stage 9: Sky Fall on these boards next week because we didn't score 50+ on a top national D.
We win something like 24-6. Sloooooow game.
So you're going to save screenshots of venting fans so you can be the hero and put them on blast in "Janurary"? Cool. Do it, tough guy. And if we don't repeat as champions, I hope you do those same folks a solid and let said screenshots "re-emerge".
This post isn't good. Have a nice day.
+1, but it's them and Alabama though. I guess I didn't pay much attention to their schedule until yesterday, and was shocked at what I saw.
And, really, how lucky of a stretch is that? You don't play any of the B1G East's traditional powers? I don't see how this team doesn't get to 10 wins.
Watching Corey Clement, especially Saturday. If he cuts loose against Bama and looking at Wisconsin's schedule (no OSU, MSU, TTUN or PSU), factored with Chryst's affair with the run, and that dude might end up going 150+ every game. Who will contain him?
Can't wait to read this same "analysis" next year once this juggernaut of a roster all heads towards Sundays!


text:
The Cooper Companies (NYSE:COO)
Q4 2013 Earnings Call
December 05, 2013 5:00 pm ET
Kim Duncan - Senior Director of Investor Relations
Robert S. Weiss - Chief Executive Officer, President, Director and Member of Science & Technology Committee
Gregory W. Matz - Chief Financial Officer and Vice President
Jeffrey D. Johnson - Robert W. Baird & Co. Incorporated, Research Division
Jonathan D. Block - Stifel, Nicolaus & Co., Inc., Research Division
Steve Willoughby - Cleveland Research Company
Kimberly Weeks Gailun - JP Morgan Chase & Co, Research Division
Kaila Krum
Lawrence Biegelsen - Wells Fargo Securities, LLC, Research Division
Joanne K. Wuensch - BMO Capital Markets U.S.
Amit Bhalla - Citigroup Inc, Research Division
Good day, ladies and gentlemen, and welcome to the Fourth Quarter 2013 The Cooper Companies Earnings Conference Call. My name is Philip, and I will be your operator for today. [Operator Instructions] As a reminder, this conference is being recorded for replay purposes. I would now like to turn the conference over to your host for today, Ms. Kim Duncan, Senior Director of Investor Relations. Please proceed, ma'am.
Kim Duncan
Good afternoon, and welcome to The Cooper Companies' Fourth Quarter and Full Year 2013 Earnings Conference Call. I'm Kim Duncan, Senior Director of Investor Relations. And joining me on today's call are Bob Weiss, Chief Executive Officer; Greg Matz, Chief Financial Officer; and Al White, Chief Strategy Officer.
Before we get started, I'd like to remind you that this conference call contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including all revenue and earnings per share guidance and other statements regarding anticipated results of operations, market conditions and integration of any acquisitions.
Forward-looking statements depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Events that could cause our actual results and future actions of the company to differ materially from those described in the forward-looking statements are set forth under the caption Forward-Looking Statements in today's earnings release and are described in our SEC filings, including the business section of Cooper's annual report on Form 10-K.
These are publicly available and on request from the company's Investor Relations department.
Now before I turn the call over to Bob, let me comment on the agenda for the call. Bob will begin by providing highlights on the quarter, followed by Greg, who will then discuss the fourth quarter and full year financial results. We will keep the formal presentation to roughly 30 minutes, and then open up the call for questions. We expect the call to last approximately 1 hour. [Operator Instructions] Should you have any additional questions, please call our Investor line at (925) 460-3663 or email email@example.com.
As a reminder, this call is being webcast and a copy of the earnings release is available through the Investor Relations section of The Cooper Companies' website.
And with that, I'll turn the call over to Bob for his opening remarks.
Robert S. Weiss
Thank you, Kim, and good afternoon, everyone. Welcome to our fiscal fourth quarter and our fiscal year 2013 conference call.
Let me start by saying I'm very proud of the fiscal year and our accomplishments highlighted, our revenue growth of 10%, our non-GAAP earnings per share growth of 15%.
Having said that, I know many of you are looking at our fourth quarter results versus our guidance. And I want to immediately provide some color on that.
Let me start with revenue. As you will have noted on our earnings release, our consolidated revenue growth was significantly impacted by our CooperVision Americas growth of only 2%. This came in around 7% wider than we were expecting and it was driven by one key item, channel inventory. This came in $7 million lighter than we were expecting and it was driven by one key item, channel inventory.
User demand has remained strong and we've seen no negative signals on that front. However, the largest 2 U.S. distributors merged and their efforts to consolidate operations and reduce inventory impacted us significantly in the month of October. This flows into gross margin as a larger portion of the lost sales would have been Biofinity to carry gross margin over 70%.
On a positive note, CooperVision Americas revenue in November was up 18%, so we are beyond the year-end reduction in channel inventory, and we're entering fiscal 2014 off to a good base.
Next, let me provide some additional color on gross margins. Cost of goods came in around $6 million higher-than-anticipated. The biggest reason for this was changes regarding the manufacturing of MyDay, our daily silicone hydrogel lens.
We made a couple of important strategic moves at the end of our fiscal year to accelerate manufacturing and expand our parameter range.
This was done to capitalize on the success we're seeing with the MyDay in the market place. Unfortunately, there isn't accounting yet, with these moves and MyDay was produced at a negative gross margin in the fourth quarter. We've done this with many products over the years, and as volume increases and as we bring on additional lines, we see these costs decrease.
It's very important to note that our manufacturing process for MyDay and our ramp-up of MyDay production is ahead of schedule, and there's no manufacturing surprises.
The fact is that demand for MyDay is very strong and accelerating in the manufacturing process for margins. This is absolutely the right strategic move and we're confident it will pay off in fiscal 2015 and beyond.
Also with respect to 2014, we're comfortable we've captured the impact of the MyDay in our guidance. For competitive reasons, I don't want to get into too many details, but I do believe we'll have sales of MyDay of roughly $25 million for fiscal year 2014. Margins will start the year very low, if not negative, but we should finish the year with margins in the upper single digits.
Combining these 2 items, the channel inventory reduction and the higher cost of goods, resulted in a negative impact on gross margins of approximately 175 basis points from where we were when we gave guidance in September.
Lastly, with respect to the fourth quarter, let me touch upon SG&A over the last couple of months of the quarter, which came in roughly $5 million higher than we originally forecast.
Again, the largest part of this was tied to our success with MyDay. MyDay has been received extremely well and recently won an award for the best contact lens product at the prestigious SILMO global optical show in Paris in late September.
Based on that, we made the decision to be more aggressive launching the product in Europe. I believe this was the right decision and we'll remain aggressive marketing this product going forward.
Totaling the 3 items, the channel inventory reduction, the high cost of goods and the higher SG&A cost, earnings per share was negatively impacted by roughly $0.30 at the end of the fourth quarter.
Let me say I'm not concerned about the end user demand and we believe we are beyond the channel inventory issue. I'm also not concerned about the production of MyDay or the demand for this product. I will discuss later -- as I'll discuss later, MyDay will have a significant impact on our P&L in coming years as it's a reduction of gross margins, not a driver of top and bottom line growth. And we believe it is absolutely a positive for our business.
Now let me spend some more time on the revenue line. Our sales are a tale of 2 cities and overall strong quarter for CVI and CSI in a very weak October in CooperVision Americas.
As I mentioned, the Americas weakness was due to the channel inventory matter, asset distributors and it negatively impacted revenues by $7 million. At the end of the day, though, end-user demand remains strong throughout the world with all of the CVI regions and core products posting solid results. This is clearly seen in the market data for calendar year Q3, but we grew 10% almost twice in the market. Additionally, in spite of the U.S. distributor issue in October, our sales in silicone hydrogel continue to drive our market share gains. Silicone hydrogel sales were up 19% in the quarter in constant currency and now represent 45% of CVI's revenues. The key driver continues to be Biofinity, on a global basis with strong contributions from all modalities, as well as all lens type spheres, torics and multifocals. In Japan, our rollout of Biofinity continues to go extremely well with sales up 2x the prior year. 2x.
Avaira had a decent quarter growing 8%, and as mentioned, MyDay rollout is very strong, constrained only by our capacity issues. Also, our Proclear 1 Day product continues to gain share with revenues up 19% in constant currency.
Once again, I'm happy to say we believe we are gaining share across the board in all regions, all modalities, all lens types, spheres, torics and multifocals and materials, be it silicone hydrogel or traditional hydrogel lenses. This demonstrates the breadth of our product portfolio. Within CooperSurgical, I'm pleased to report sales growth of 8% led to our -- led by our IVF franchise, which grew 24%.
Stock geographically. Foreign exchange headwinds continue reducing CooperVision revenue 3% in the quarter. Excluding foreign exchange, CooperVision growth was 6% in the fiscal quarter.
Last year, the euro was down 7%. This year, the yen was down 19% in the fiscal year and 25% in the fourth quarter compared to the prior year. With $200 million of revenue in Japan, this is not only impacting our revenue, but it's also negatively impacting our gross margin, as well as our operating income and our bottom line. Even with the major -- this major nuisance on the strength of the product lines we are putting up some solid numbers.
From a revenue perspective regionally, we have put up solid constant currency growth except for the Americas, which was impacted in October by the 16% decline in days in inventory at authorized distributors.
Regionally, the Americas is up 2% in the fourth quarter in constant currency; Europe, 8%; Asia-Pac, 11%; and worldwide, 6% in constant currency.
Our growth drivers are: In the Americas, trading up to Biofinity, including the halo effect of Biofinity; multifocal with the entire family doing well; also while off of a smaller base Proclear 1 Day, sphere and multifocal is a key contributor.
In Europe, right now, currency is helping offset some of the yen, driving our 8% constant currency growth in this region is the entrée -- the entire Biofinity family and the 1 Days, including MyDay.
In Asia-Pac, while foreign exchange took its toll on revenues, our constant currency revenues were up 11%, 12%, excluding Aime. Drivers, the tremendous success of the Biofinity family, especially with the halo effect of Biofinity toric and the Proclear 1 Day.
Let's talk a little bit about the marketplace. The worldwide soft contact lens markets. In the third calendar quarter, 2013 was up 6% in constant currency. While CooperVision was up 10%.
For the trailing 12 months ended September 30, the soft contact lens market now at $7.4 billion worldwide was up 5% in constant currency.
CooperVision was up 10% on the strength of Biofinity and Proclear 1 Day. For the calendar quarter, the market growth was sponsored by 1 Day growth, which is up over 10%. While industry growth data is no longer available on silicone hydrogel material, most likely this trade up of material remains a solid growth driver.
CooperVision was up 23% in constant currency in the calendar quarter, third quarter of 2013. And at CooperVision, silicone hydrogel now represents 45% of our revenues. The soft contact lens market continues to be a trade-up market. This includes premium products silicone hydrogel, lenses, torics and multifocals.
The trade up to 1 Day disposable expands patient revenue by 400% to 600%. Even more important, the 1 Day wearer generates 300% to 500% more profit per patient.
Also, it's important to understand that torics and multifocals have a long way to go in capturing the market opportunity, especially outside the United States.
Geographically, the Americas did best, up 7% in the calendar quarter on the strength of the 1 Day trade up. Asia-Pac, 6% on the strength of a 10% growth, excluding Japan; and in Europe, it was up 4% also on the strength of the 1 Day trade up.
CooperSurgical, our women's health care franchise turned in a solid $84.8 million in revenue, up 8% with the prior year fourth quarter. On the strength of a $29 million contribution from fertility, which accounts for 34% of CooperSurgical and was up 24% above the prior year.
I'll talk briefly about guidance. We have now provided more color on what we think fiscal year 2014 will bring. We remain bullish about top line growth and gaining market share. We expect upper single-digit top line growth with CooperVision growing close to double digits in constant currency and continuing to outpace the market.
Our assumption is that the soft contact lens market will continue to grow in that 4% to 6% range. Between Biofinity, Proclear 1 Day, and now, MyDay, we have the products to address the growth areas of the global soft contact lens market.
On the profit side, we will have a few ongoing challenges. Clearly, the yen will stay a headwind at least through the first 6 months of the fiscal year with the prior year comps for the yen being 85 in the first quarter last year and 95 in the second quarter.
The other muddying factors will be the ongoing expense of the MyDay rollout and the numerous capital expansion programs we are in the middle of. Also, geographic expansion will continue on several fronts. Even so, we remain optimistic that Biofinity will continue to deliver good top line, gross margin percent and operating profit to fund many of our ventures.
The net results is we expect to deliver very respectable growth in non-GAAP earnings per share in the 13% to 18% range or the $6.70 to $7 in our guidance in the fiscal year 2014.
2014 will be another year of heavy commercial -- heavy commitments to capital expenditures. We expect capital expenditures will exceed $200 million. Even so, we again except to deliver in excess of $200 million of free cash flow.
One more point before I leave guidance. I, for several years, have been very clear and very deliberate about saying we will forgo our greatly improve gross profit percent for the trading up to the 1 Day modality. That is expected to deliver 400% to 600% more in top line revenue per patient. And longer-term, 300% to 500% more profit per patient.
This will come at the expense of the lens care industry. We remain committed to the strategy into our 2018 objective of a 25% operating income margin.
Other contributions in the 2014 to 2018 period include the rolloff of the CIBA royalty, the elimination of the 10-year amortization period on the Ocular Sciences acquisition in January 2005, it roll offs in 2015, the beginning of the expiration of depreciation on many of the Gen II lines that came with the Ocular acquisition and additionally, the expiration we will begin -- and additionally, the expectation that we will begin leveraging some of the investments we've been making in global sales and marketing and R&D the past 6 years. All in all, we believe a 25% operating income target for 2013 is achievable.
One thing I have historically put much color -- not put much color on is how we have done the first month following the quarter. Breaking with tradition, given my earlier comments about the 16% shrinkage in the U.S. authorized distributor pipeline, I thought I would add some color.
In November, CooperVision's revenues were up 5% as reported but up 12% in constant currency excluding Aime. The Americas were up 18%. These November results have been factored into our fiscal year 2014 guidance.
Enough on guidance and outlook. Today, I'm going to skip some of the traditional comments on strategy to allow a bit more time to have Greg review the financials and for questions-and-answers.
So in summary, before I turn it over to Greg, let me say how pleased I am -- I remain with our results. We continue to outperform the marketplace, most recently growing in the neighborhood of 2x the market for soft contact lenses.
Our family of products: Biofinity, Avaira, Proclear 1 Day and MyDay and in the women's health care fertility all have promising growth potential in the global marketplace. We have continued to invest in global expansion and are making good progress in many of these markets. Our balance sheet and our free cash flow are strong, and we'll fund our global expansion plans as we aggressively move into the 1 Day market, which accounts for over 40% or $3 billion of the $7.4 billion soft contact lens market worldwide.
While we are more than willing to trade off our gross profit for 1 Day top line, we will do this in a manner that increases our operating income margins and earnings per share. We remain keenly focused on delivering improving results, mindful of our desire to invest and leverage prudently, thereby, delivering optimized, long-term total shareholder returns.
I might add, we purchased almost 1 million shares of our stock in the fiscal fourth quarter, and will continue to do this if we believe it makes sense.
Lastly, as always, a reminder that at Cooper, our #1 asset is our employees. I wish to continue to express my appreciation for their dedication to creating great results.
And now, I'll turn it over to Greg to cover more of the financial highlights.
Gregory W. Matz
Thanks, Bob, and good afternoon, everyone. Bob shared with you a pretty through review of the market and our revenue picture. Bob also gave you the highlights of our Q4 gross margin and earnings per share versus our expectations we had shared in guidance on September 5. Let me start with gross margins looking at the full fiscal Q4 '13 versus Q4 '12.
In Q4, the consolidated GAAP and non-GAAP gross margins were 64.1% compared with 63.8% for GAAP and non-GAAP in Q4 last year. We continue to see strong headwinds year-over-year due to the impact of foreign exchange, predominantly the yen, on our revenue and the related direct impact on gross margins, which had approximately a 95-basis-point impact year-over-year. We're seeing a large impact to margins of approximately 70 basis points due to MyDay and a combination of mix and start-up costs.
As we discussed in the past, we've been fluctuating between low and no margins on this product, which is normal in the start-up phase where you're building capacity.
Helping to offset the headwind has been favorable product mix, excluding the impact of MyDay and the CIBA royalty savings. On a full fiscal year basis, we finished at 64.7%, up 80 basis points from the prior year.
CooperVision, on a GAAP and a non-GAAP basis, reported gross margin of 64% versus 63.7% for GAAP and non-GAAP in Q4 last year. Factors impacting gross margin in the quarter, as I mentioned, are the currency headwinds, MyDay and the CIBA royalty savings. For the full year, gross margins went from 63.4% in 2012 to 64.8% in 2013.
CooperSurgical had a GAAP and a non-GAAP gross margin of 64.3%, which compares to Q4 '12 of 64.1%. Fertility with lower margins will continue to put pressure on our gross margin, but we still expect CooperSurgical's margin to be modestly higher in fiscal 2014.
For the full year, CooperSurgical's margin went from 66.4% in 2012 to 64.2%, 2013. The reduction was largely due to the purchase of Origio in July 2012, which expanded our presence in the IVF space.
Now looking at operating expenses. SG&A in the quarter on a GAAP basis, SG&A expenses increased by 3% from Q4 last year to $157.2 million, and were 38% of revenue, same as the prior year.
On a non-GAAP basis, SG&A grew 4% year-over-year. Now the difference is that GAAP SG&A for Q4 '12 included $800k of Origio integration costs.
As Bob previously mentioned, during this past quarter, we did experience higher selling and marketing expenses than planned as we ramp some of our product launch efforts for MyDay in Europe. On a sequential basis, SG&A was up 3%.
As we discussed in the past, CooperSurgical is impacted by the medical device excise tax. We had 736k of medical device excise tax in the quarter hit SG&A. We had a total of about $2.4 million hit in 2013, but we would expect to see around $3 million for this tax in 2014.
Now looking at R&D. In Q4, R&D increased by approximately 12% year-over-year to $15.8 million, or up $1.7 million. R&D was 3.8% of revenue, up from 3.6% in Q4 '12. We expect R&D will continue to grow faster than sales in fiscal 2014.
Depreciation and amortization. In Q4, depreciation was $24.1 million, up 560k or 2% year-over-year, and amortization was $7.7 million, up approximately 400k or 5% year-over-year for a total of $31.8 million. For the year, depreciation and amortization were $95.1 million and $30.2 million, respectively, for a total of $125.3 million.
On October 31 this year, we completed a transaction to sell Aime, our rigid gas permeable contact lens and solution business in Japan, to Nippon Contact Lens Inc. The business was originally obtained as part of the December 2010 acquisition, which included obtaining the rights to market Biofinity in Japan. The divestiture is consistent with CooperVision's strategy to focus on its core soft contact lens business.
The company recognized a fourth quarter GAAP charge to earnings under the line of loss on divestiture of Aime in the amount of $21.1 million. This will have a GAAP EPS impact of $0.28 for the quarter and $0.26 for 2013. Going forward, this is expected to be neutral to earnings per share.
Moving to operating margins. For Q4, solid consolidated GAAP operating income and margin were $62 million and 15.1% of revenue versus $79 million and 19.9% of revenue in Q4 '12.
On a non-GAAP basis, operating income and margin were $83.1 million and 20.2% of revenue versus $79.8 million and 20.1% for non-GAAP in Q4 '12. This represents a 4% increase in operating income over Q4 '12 non-GAAP numbers.
The difference in the current year between GAAP and non-GAAP operating income is the $21.1 million Aime charge. For the full year, GAAP operating income and margin were $305.9 million and 19.3% of revenue, up 8% in operating income, down 30 basis points on the margin.
On a non-GAAP basis for the full year, operating income and margin were $327.6 million or 20.6% of revenue, up 13.7% and up 70 basis points on the margin, respectively. Interest expense was $1.9 million for the quarter, down 30% year-over-year.
In looking at the effective tax rate. In Q4, the GAAP and non-GAAP effective tax rates were 6.2% and 10.3%, respectively, versus Q4 '12 GAAP and non-GAAP effective tax rate of 12.7% and 13%, respectively.
As we've discussed before, the effective tax rate continues to be below the U.S. statutory rate, as a majority of our income is earned in foreign jurisdictions with lower tax rates.
The full year GAAP and non-GAAP effective tax rate were 4.9% and 7.4%, respectively, versus 2012 rates of 9.7% for both GAAP and non-GAAP.
Looking at earnings per share. Our Q4 earnings per share on a GAAP and non-GAAP basis was $1.15 and $1.48, respectively, versus $1.46 and $1.47 on a GAAP and a non-GAAP basis in Q4 '12.
Earnings per share is down 21% on a GAAP basis, largely due to the $0.28 charge for Aime in the current quarter and the $0.10 benefit in Q4 '12 from insurance proceeds.
On a non-GAAP basis, EPS is up 1% or $0.01 versus the prior year. In Q4 '12, the non-GAAP earnings also benefited from the $0.10 favorable impact of insurance proceeds.
As Bob discussed, our Q4 earnings per share was impacted negatively by U.S. distributor inventory reductions and certain items in cost of goods sold and operating expenses led by decisions to support our MyDay product.
For the full year, our earnings per share on a GAAP to non-GAAP basis was $5.96 and $5.95, respectively, which is a growth of 18% and 15.3% GAAP and non-GAAP, respectively.
During Q4, we repurchased approximately 960,000 shares with an average share value of $128 per share for a total cost of $123 million. This makes a total shares repurchased during 2013 approximately 1,421,000 shares, at a total cost of $167.3 million or $117.78 per share. This leads the remaining $61.6 million available for future share repurchases under the current approved program. The earnings per share impact of our 2013 share repurchases is $0.01 in Q4 and $0.05 for the full year.
Regarding foreign exchange, currency continues to have a big impact on our business. From a year-over-year perspective, currency negatively impacted us by $0.12. And this was mainly driven by the yen, which is down 25% year-over-year.
For the full year, we saw a $0.50 EPS impact due to currency. At the current FX rate, we'd expect an approximate $0.21 negative FX impact in EPS next year, which is baked into our guidance. For our 2014 guidance, we use today's rates of roughly 1.36 for the euro, 102 for the yen and 1.64 for the pound.
Looking at balance sheet and liquidity items real quickly in Q4, we had cash provided by operations of $150.3 million, capital expenditures of $72 million, resulting in a $78.3 million of free cash flow. For the year, our free cash flow was $239.4 million. CapEx for the year was $178.1 million.
On September 16, we announced the company closed a $300 million, 5-year senior unsecured term loan, which matures September 12, 2018. We use the facility to pay down borrowings under our $1 billion senior unsecured revolving line of credit, which matures May 31, 2017.
This term loan provides additional financial flexibility through an improved maturity structure, additional capacity and lower interest rates. Total debt increased within the quarter by $101 million to $344.7 million due to $123 million of share repurchases. This leaves us with approximately $1 billion of total credit available at October 31.
Inventories were basically flat at $339 million from last quarter. For the quarter, we're seeing months on hand at 6.9 months, up from a months on hand, 6.7 months last year and down from 7.1 months last quarter.
Accounts receivable continues to be well managed with DSOs at 53 days, down slightly from 54 days last year, and the same as the end of last quarter.
Now turning to guidance. In order to provide a little bit more color for your models, let me share some additional specifics on our guidance. Revenue range for the company is $1.675 billion to $1.735 billion. CooperVision's revenue range is $1.355 billion to $1.395 billion. And finally, CooperSurgical's revenue range is $320 million to $340 million.
We expect non-GAAP gross margin to be around 65% for the year, and slightly less than the first half as we make progress on the MyDay ramp-up, specifically around reengineering current equipment for MyDay.
We continue to expect efficiencies in manufacturing process, positive impact due to Biofinity, offset by MyDay and currency, especially the pound impact on manufacturing as we look at rates up into the 1.64 range. As we stated in the past, just under 50% of our production value is produced in the U.K.
OpEx, we're expecting around 43%. Amortization at $28 million for the year, with around $7.4 million in Q1 and Q2 and Q3 and Q4 would each be about $6.7 million.
R&D is expected to grow slightly faster than revenues. Operating margin is expected to be around 22%, interest expense to be around $8 million, our effective tax rate is expected to be in the range of 8.5% to 10.5%. Our earnings per share, as Bob mentioned, for GAAP and non-GAAP is expected to be in a range of $6.70 to $7.
Finally, we expect capital expenditures and free cash flow for the year to be above $200 million.
With that, let me turn it back to Kim for the Q&A session.
Kim Duncan
Operator, we're now ready to take some questions.
Question-and-Answer Session
[Operator Instructions] And your first question comes from the line of Jeff Johnson from Robert Baird.
Jeffrey D. Johnson - Robert W. Baird & Co. Incorporated, Research Division
Bob, I just want to go back to your comments on the 25% operating margin in fiscal '18. And Greg, you laid out a plan here of maybe 130, 140 basis points of margin expansion in fiscal '14. So from fiscal '14 to fiscal '18, Bob, obviously, you're going to have a lot of moving parts as MyDay becomes an even bigger part of the mix. You obviously have some things coming off on the IP side and also on the amortization side. But wondering, as you paint the picture going from 20%, 20.5% this past year to 25%, is it up a pretty consistent 100, 150 basis points a year each of the next 5 years? Or when we get beyond fiscal '14, is there risk that we may be flat now that the margin line for year or 2 with MyDay has a bigger impact before then seeing a nice a kind of tick up from there?
Robert S. Weiss
Jeff, I think it's going to be -- I don't want to say smooth, but 2015 should be an okay year relative to 2014 and then when you move into 2016 likewise you have some favorable events. So as I see it, it's maybe not a straight line going up from 20% to 25%. But it shouldn't be a hockey stick, meaning we hang out at 21.5% to 22% until the last 2 years, that's not the way I see it. I see it improving somewhat every year.
And your next question comes from the line of Jon Block from Stifel.
Jonathan D. Block - Stifel, Nicolaus & Co., Inc., Research Division
I guess, maybe I'll just try to wrap this up in one question. Can you just speak a little bit, Bob, to MyDay? It's been out there in Europe, the pricing. And then you talked a little bit about manufacturing. It seems like hitting the gas there, you now have approval in hand with the U.S., but you're seeing strong demand in Europe. So can you talk to -- is Europe pushing out the U.S. because you want to make sure that you're feeding those mouths? Or you're trying to hit the gas even come to the U.S. sooner?
Robert S. Weiss
Jon, we're obviously very pleased with the progress we're making in Europe, and following good military guidelines, you don't overextend yourself and then tick off everyone. So Europe is obviously in the queue first up. And suffice it to say, that means depending on how Europe is going will influence the timing in the U.S. Having said that, on the other front, on the supply end, we're doing everything we can do to accelerate within reason the production side, and obviously, because of the long lead times somewhat problematic to just kind of wish it all here to mark and it's just not going to happen. But Europe is doing very well. The gold award at the SILMO Conference, best product there, we gave it a better shot on the arm. One of the things we did do is deliberately round out the product portfolio, which means build out the plus powers, as well as the minus powers. And that obviously was done with the intent of giving the customer a better product line to pick from and it did cost us short-term in terms of yields, it cost us short-term in terms of cost of goods. We just think there is the right kind of decisions to make. But to answer your question about the timing into the U.S., we'll probably get here sometime next year. But at #1, it won't be robust. #2, it is somewhat influenced by Europe.
Your next question comes from the line of Steve Willoughby from Cleveland Research.
Steve Willoughby - Cleveland Research Company
Just a question on the MyDay, and what that product kind of looks like going forward. For gross margins to kind of get into the -- maybe let's just say 40% to 50% range where other 1 Day lenses are. Can you maybe walk through kind of what needs to happen there? Is it just a matter of increasing your capacity and volume for that product? Or do we need some sort of kind of break through the manufacturing process in order to get the margins up on that product?
Robert S. Weiss
Steve, I guess I would describe it this way. There are some easy fixes and easy improvements, getting the first -- getting to the right zone, so to speak. So we have a pretty good map of where we are going the next 3 or 4 years by way of improvements in the equipment. We're manufacturing improvements in the yields on the existing lines. When you then get down to the point where maybe you're approaching 40% margins, moving the next 10 gets a bit more challenging, and you have to find those ideas sooner rather than later if you're going to alter some of the equipment or modify the equipment. So it's very much like the description of 20% OI, going into 25, it's going to happen in steps along the way. But directionally, it will -- we'll get a good way down the path.
And your next question comes from the line of Kim Gailun from JPMorgan.
Kimberly Weeks Gailun - JP Morgan Chase & Co, Research Division
Question on MyDay, at what revenue level do you think that MyDay becomes operating margin-neutral? Yes, you talked about some of the gross margin ramp that you're expecting in '14, but I also imagine you're going to be spending on sales and marketing behind the MyDay rollout. So at what level should we think about that becoming a product that's closer to kind of operating margin neutral relative to the corporate average?
Robert S. Weiss
Kim, many products that we roll out like this, be it Proclear 1 Day, be it Biofinity, quite frankly for several years, didn't make operating profit. And for sure today, it makes operating profit. We're going to look at how much muscle at any point in time we have by way of capacity and how many markets we have available to dictate that. So my expectation is that it is unlikely we will be making profits on MyDay the next several years with the intent of continuing to develop that franchise, continuing to drive down cost of goods, but we'll be putting a fair amount of muscle as the capacity increases behind the product once we come to the U.S. and then once we go into other markets around the world. So it isn't -- if we wanted to make money, clearly, we could kind of map out the European model, invest 1 year and start reaping profits as early as 2 years from now, but I don't think that's the right model and I truly hope that the product has more legs so that we have investment opportunities even post the 2-year period. So I don't want to assign any $1 amount and say, chief, if we get to $100 million, we arrive at profitability. Cost will be coming down, no doubt, as you ramp up and it's $100 million product line instead of a $25 million product line, but there are other valuables that we'll consider in drawing that line.
And your next question comes from the line of Matt O'Brien from William Blair.
Kaila Krum
It's Kaila in for Matt. First off, I was wondering to get a little bit more color on the channel inventory issues that occurred this quarter. And if you can just help us understand, what gives you the confidence that those issues won't linger into 2014?
Robert S. Weiss
Kaila, good question. The confidence we really have is, a year ago, some of you may remember we had a reduction in channel inventory, and that reduction was around 20% in the authorized distributors here in the United States. I'm talking principally about the U.S. now. And so we assume that, that probably would be where it would settle out. Then during the course of this year, the merger came along, off the 2 largest distributors, or certainly our 2 largest distributors in the United States. And we kind of knew maybe something would happen that would, they had different model and we weren't sure which model would preempt which and in what time frame and what the implication would be. So it turns out we found out at the end of the fourth quarter that those levels were going to come down to a pretty tight level. It's our best view that that's where it's going to settle out. That means that in 2013, we really lost arguably 1 to 2 weeks of sales to distributors in the year, and therefore, we quite frankly have slightly easier comp in 2014 than we do in 2013 as a result of that phenomena. But we think based on what we saw in November and month to date in December that we have a handle on the fact that they got it down to the level they want and its business as usual going forward.
Kaila Krum
Okay, that's helpful. And then just on MyDay, you've mentioned that $25 million estimate in 2014. Does that assume any sort of contribution from the U.S. next year?
Robert S. Weiss
No. Nominal.
The next question comes from the line of Larry Biegelsen from Wells Fargo.
Lawrence Biegelsen - Wells Fargo Securities, LLC, Research Division
I'm trying to understand if the items in the fourth quarter that hurt you by $0.30 on the EPS line, we should see them as onetime or not? And if they're onetime, then your EPS would have been about $6.26 for the year and the guidance for 2014, then the implied guidance will be 7% to 12% growth, not the low double digits that you said in the third quarter call. So if you could help me understand that, that would be helpful. And Bob, on the gross margin, I heard the 65% for 2014 in the guidance and then I heard obviously, your commentary earlier. Can you talk about what -- how is the gross margin progression looks over the next few years given some of the headwinds and tailwinds even directionally, do you think the gross margin can go up or should we kind of model it flat for the next few years?
Robert S. Weiss
As far as how much is reoccurring and how much is not reoccurring, clearly, things like the authorized distributor shrinkage in 2013 should not repeat and should be viewed as nonrecurring. So that's kind of a step up of be it -- in a $0.10-plus or minus. So that gets you, if you will, from $5.95 to $6.05. When it comes to those things surrounding MyDay, that is not black and white. Some of it was onetime, within that pot, such as taking a machine down and retooling it for the MyDay operation. Some of that will, if you will, once you get into production away. Having said that, some of that activity continues into 2014. So there will be some repeating of some of the events in the fourth quarter into 2014, which is built into our full year guidance. So I think the comp is not at either extreme, not at $5.95 compared to, let's say, the midpoint of $6.85, just to pick a number within that range, nor is it at the -- I add $0.30 to the $5.95 and then do the comps. It's some place in the middle of 30 and then 0. On the second question of gross margins, where did they go from here? There are a number of moving parts, there's no doubt the royalty, there's no doubt things like depreciation, there's no doubt MyDay. There is no doubt the remnants of foreign exchange, which have played havoc on us in the last 2 years. How you look forward, the 65 going down the road to 2018, some of that will be the more successful we are with MyDay, the more pressure we obviously put on that gross margin going forward. And I think I've indicated several times, I really don't care if it turns out to be 1 Day is 50% of our portfolio, our gross margin undoubtedly will be lower than 65%. And I kind of hope that happens because it obviously is good for our operating income line and not only the top line growth but the operating income growth. So I would assume that the 65 going forward has some potential pressure on it if we're extremely successful with MyDay. Beyond that, if it's kind of middle-of-the-road, we have a fair amount of good things going that may minimize some of the mix issues by MyDay. Whether or not that leads to 65 or some modestly lower, I don't know quite frankly.
Your next question comes from line of Joanne Wuensch from BMO Capital Markets.
Joanne K. Wuensch - BMO Capital Markets U.S.
The channel inventory situation, which segment of CVI did that impact the most? And do we assume that the entire rolloff that happened in the fourth quarter comes completely back on? And then my second question is, is the operating margin for CSI don't really seem to be recovering from the Origio acquisition. And can you talk about plans to help that move forward too?
Robert S. Weiss
First of all, on the channel inventory, which comes from CVI U.S., and I think we indicated that a fair amount what that distributor gets, which is the U.S. profile, if you will, of products, excluding the limited volume SKU for torics, for example, which we shipped direct and they don't go through the distributors. So our large distributor takes the entire breadth of the U.S. product line of CooperVision x the stock keeping units that don't make sense to carry at that level. As far as the impact, the impact was on the fourth quarter. We are expecting that, that level, that new level of inventory on hand will stay quarter-by-quarter hereafter, which is to say, no new collapse, no new comeback. It's not going to step up, it's not going to step down, it's going to stay steady-state, that's our underlying assumption. There is some modest tweaking that goes on within the quarterly cycles for cyclical reasons, but it is fairly modest, it's nothing like what we're talking about at year end. As far as the operating margins of CooperSurgical, will they rebound to where they were pre-Origio? Origio, number one, is a very global acquisition. And as you go global, building out that structure, it's going to operate a little less efficiently by nature than having a U.S.-centric business where make it in the U.S., ship it in the U.S., that's all there is. So that's one downward pressure. Second thing is, we continue to invest in Origio as it builds itself out globally, and grew 24% this last quarter. And as long as it's putting up good growth numbers, we will continue to invest and not try to reap the profits on that. The one thing we do have in mind, however, is ultimately fine-tuning its production process, I guess, in a sense of product mix and profitability on the gross margin line. And I would hope that as we look forward over the next several years, we improve somewhat on its gross margin.
And your next question comes from the line of Amit Bhalla from Citigroup.
Amit Bhalla - Citigroup Inc, Research Division
Two quick ones for Greg. Greg, just number one, share count guidance for '14. And second on Aime. I just want to reconcile on a non-GAAP basis the charge and the impact on revenues into earnings to the fourth quarter based on Aime.
Gregory W. Matz
Okay, Amit. The first thing, the share count is 49.5. And so for Aime, if you look at Aime, there are a couple of pieces, one, the charge was, the $21.1 million we mentioned. It had for the fourth quarter, $0.28 impact. For the year, it's $0.26 and that difference is really around taxes. There was a tax true up in there so -- and you actually had some additional $0.05 of tax true up in the quarter. So if you look at the difference between GAAP and non-GAAP, you see $0.33 and that really is an additional $0.05 on top of the $0.28 Aime. Or it's a typical tax true-up at the end of the year. You estimate your rate throughout the year. Once you hit your end, finish your provision, you're able to go back in and exactly hit what your tax rate will be. So nothing unusual.
Ladies and gentlemen, does that conclude the question-and-answer portion of today's call. I'll now turn the call back over to Bob Weiss for closing remarks.
Robert S. Weiss
Well, thank you, everyone, for participating in today's call. We are obviously very excited as we look down the road to 2014. I think you can tell that from our guidance, we're feeling pretty bullish about what is going through the pipeline. We're very bullish about MyDay, and look forward to talking to you a lot more on our first quarter conference call about our progress in some of these areas as we go forward.
With that, I think our next conference call is on March 6, if I have it right, of 2014, which is a Thursday. And we look forward to updating you at that point in time. Thank you.
Ladies and gentlemen, that concludes today's conference. Thank you for your participation, and you may all now disconnect. Have a wonderful day.
Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.
If you have any additional questions about our online transcripts, please contact us at: firstname.lastname@example.com. Thank you!


text:
Jeff Bell received the phone call that every parent fears. His son Brian, a young man full of potential and promise, had been killed on the job. In this powerful presentation, Jeff Bell introduces his son Brian and takes the audience step by step through the events leading to his death. During his presentation, Jeff, an experienced safety facilitator for a large paper mill, takes every opportunity to explain what is required to prevent such tragedies.
If you have reviewed this product please comment below or select the comment count.
For more information please contact us– Thank you.


text:
Georgia PumpThursday, July 17, 2008
I would likely buy this in black, but I love pretty much everything about this shoe.
Kate Spade Georgia Pump
No comments
I love comments! Please ask away, provide info on how you liked something, etc. Note that spam, comments with random links (which I count as spam), anything not in english (again, spam) and comments that are completely unrelated to anything will all be deleted.


text:
Other People's Money: Satirical Play on Shifty Financial Dealings
Our Price
Full Price
With biting social commentary that's as timely as today's financial news, Other People's Money is a satirical and sexy comedy. This witty tale of opposites centers on Wall Street profiteer Lawrence Garfield, a shark who wants a small, struggling company as his next corporate meal -- if only he can get past the feisty young attorney hired to fend him off. The raider's attraction to the smart and beautiful opposing counsel (who matches his wit and his gamesmanship) may prove to be his undoing -- or the key to his happiness.
* Additional fees apply. No coupon or promo codes necessary to enjoy the displayed discount price.
All offers for Other People's Money have expired.
The last date listed for Other People's Money was Saturday April 12, 2014 / 7:30pm.
Most Popular Theater Event Nearby
Airbnb, Group Tours, Economy Class Woes: Are We Almost There? The Travel Musical
- Full Price:
- $30 - $34
- Our Price:
- $15 - $17
"Are we there yet?" The journey is the best part -- or so they say. Are We Almost There? The Travel… More
Venue Details
Reviews & Ratings
"Other People's Money"
Featured review from steve schaffer
view more less of this review
the musical itself was mediocre, but westminster didn't improve things. dunno why it was chosen.
More Information


text:
Related Quotes
20 mins - disclaimer
Tuesday January
11, 9:16 am Eastern Time
Alert: Warburg Cuts
Wackenhut Corrections Price Target to $15/Shr From $24
(This is a headline-only alert, although it will likely
be followed by an article soon)
RESEARCH ALERT - Wackenhut Corrections
NEW YORK, Jan 11 (Reuters) - Warburg Dillon
Read said Tuesday analyst Thomas O'Halloran lowered
estimates and price objective for Wackenhut Corrections
Corp. <WHC.N>, explaining the company recently
guided investors to lower earnings levels for the fourth
quarter of 1999 and all of 2000 in light of higher
operating expenses, larger start-up costs, and slightly
lower revenue.
"Our estimated 1999 EPS from
operations has been lowered to $0.94 (from $1.00) and our
2000 EPS estimate goes to $1.00 (from $1.20)," the
analyst wrote, setting a new price target of $15, down
from $24.
The stock closed Monday at 10-1/4.
NEW YORK, Jan 11 (Reuters) - Warburg Dillon Read
said" Price target of $15.00" thats a multiple of 15 x
earnings. If we get a 15 multiple for PZN we can be in good
shape in a a years time. . .Some analyst estimate a
EPS for next year that puts us at $15.00.
wouldn't we be a private company? I don't see how a private company can purchase a Listed company and end up being a Public company, unless OPCO then did an IPO.
I mean no disrespect, but does anyone really
know: 1. how action can be taken by stockholders to
terminate Doc and Doc jr from the company without any form
of compensation?
2. how the stockholders can
salvage some of their investment and block the circling
vultures? 3. can any of the principals currently at the
table be trusted?
I agree with an earlier comment re
Mike Q.
At least when he was with BOP he was
regarded as honest, capable, and, more importantly,
competent. Clearly, PZN/CCA is the major mover in the
business of prisons, I guess it just needs to be
I don't think that would be a problem, just means
Opco is now public. Normally this type transaction is
called a "reverse shell". One other way to go public
other than an IPO is for a private firm to buy a public
firm/ or shell. Browning Ferris Industries (BFI) was a
reverse shell. It's a lot cheaper to go public as a
reverse shell than an IPO. Lawyers sell public shells for
anywhere from $80k and up.
I thought I was complying with your wishes!!
Take My Advice Completely, Kind Excellent Reader
I didn't know any of that; thanks.
I'm beginning to question why I'm spending 50% of my time on a stock that comprises 5% of my portfolio. Ever wonder the same?
spending so much time on a stock that is 5% of my
portfolio, but used to be 20%. What is hard to take is that
Doc doesn't take the same kind of cut in his net
worth that the common shareholders do. Now some will
call that whining, and counsel us to bend over and
take it like a man. If we try to fight back, we're
called sore losers. As Nixon once said, "show me a good
loser and I'll show you a loser."
The most convoluted, arcane, unintelligible part
of the Internal Revenue Code is the part concerning
the taxation of corporate reorganizations. A straight
merger would work, but there are also a bunch of other
Meanwhile, from the SEC filings, CCA is bankrupt.
Liabilities exceed assets by $62,554,000. What are the
shareholders of CCA to receive, according to the proposal? If
they receive anything, it is a fraud on the
shareholders of PZN, IMO.
The perpetual statement that
we need CCA troubles me. For $62,554,000, you could
set up a new management division, with a clean slate,
and no debt.
Another thing that troubles me is
that CCA shows a $6,500,000 expense for the use of the
name CCA. Paid to whom?? Why? Are we supposed to
assume that expense? Call the damned thing Acme Prison
Company! That looks to me like another waste of our
Wile E.
You raise good questions.
I imagine Doc
has provided himself a nice golden parachute prior to
this, and has gold plated it with the
Personally, I would like to see a shareholders' group sue the
company and Doc to prevent him from taking anything from
the table, other than the shrunken value of his
stock. He has, IMO, defrauded the shareholders, and
through his dihonesty and incompetence, caused this whole
The problem is that the lawyers who represent
shareholders are vultures, ready to take whatever they can,
and leave a little for their clients. They would not
benefit from obtaining an injunction preventing Doc from
raiding the till on the way out the door, so they
wouldn't be interested in filing the case.
Wile E.


text:
Occotis 3301 Slim Jeans
€ 149.95 including tax
Occotis 3301 Slim Jeans
€ 149.95 including tax
Colour Raw Denim
This item is currently not availablefind in local store
3301The 3301 is a classic 5-pocket jean and represents the cleanest style in the G-Star denim range. Based on the hardwearing labourer's pant of Western origins, which was known for its 'non-fit', the 3301 is a wardrobe staple. Its name is derived from the fabric and colour code of the first raw denim introduced by G-Star in 1996.
Combining the timeless simplicity of the 3301 with progressive ocean-friendly denim, these slim jeans feel as good to own as they do to wear. Wear them with pride and become a part of the solution.
- Fitted waistband
- Regular rise
- Narrow legs
- Button fly
Model is 1.90m and is wearing a size 33/32 (Waist {waist}, Hips 100cm). View size guide
The Occotis 3301 Slim Jeans is crafted from indigo denim, woven using Bionic Yarn, an innovative yarn containing recycled ocean plastic.
- Classic denim texture
- Traditional denim feel
- Ocean friendly
- 86% cotton, 14% polyester
Untreated and pure, ready for you to break in and make your own.
Washing instructions
- 40° normal process
- Do not bleach
- Do not tumble dry
- Line dry / Hang to dry
- Low temperature iron 110°
- All solvents except trichloride
- w54
- w76
- w70
Art nr: 20.0.D01491.7768.001


text:
National Ovarian Cancer Coalition, Inc.
Rating: 3.75 stars 4 4 reviews
2501 Oak Lawn Avenue Suite 435 Dallas TX 75219 USA
NOCC's mission is to raise awareness and promote education about ovarian cancer. The Coalition is committed to improving the survival rate and quality of life for women with ovarian cancer.
Over 77% of income supports NOCC programmatic initiatives.
Faces of Hope (Survivor support and quality of life), Teal Initiative (Education and Awareness), and Run/Walk to Break the Silence on Ovarian Cancer (Fundraising and community awareness)
Filter Reviews by Role
Promote This Nonprofit
GreatNonprofits badges allow you to raise awareness of your favorite nonprofits on your own web sites!
Reviews for National Ovarian Cancer Coalition, Inc.
My mother currently battling this devastating disease. I participate in the Pittsburgh chapter walk ever year. Think is a great organization that is not as highly recognized as it should be. Unfortunately some many signs of this disease go unnoticed until its too late and this org makes greats strides to try to create awareness
More Feedback
Will you volunteer or donate to this organization?
How much of an impact do you think this organization has?
When was your last experience with this nonprofit?


text:
May We Suggest
Description: Kopul Dental Clinic is located in Ede Road, Etal (Formerly Excleisor) Hotel Premises,, Apapa, Apapa
Description: We provide quality and comprehensive dental care for patients of all ages in a comfortable and frie
Description: We offer simple solutions for by providing a wide range of premium dental care services to patients
Join VConnect to do this
Find your friends who are already here. VConnect helps you to discover great places around you.
Get quote from businesses
Create a list
Add related businesses for you and share them with your friends.


text:
News By Tag
Industry News
News By Place
Industry News
The Radisson Blu Hotel, Bristol announces the appointment of a new General Manager
The Radisson Blu Hotel, Bristol has announced the appointment of Christopher Peach as its new General Manager
Christopher has an extensive background in the hospitality industry, spanning 23 years. Having started his career in 1987 as Commis Chef aboard the Queen Elizabeth II cruise liner, he has since held various management positions at different international hotel chains in South Africa, China, Bahrain, UAE, Turkey and Russia.
This new appointment has Christopher returning to his native Britain, where he will manage one of only a few waterfront hotels in Bristol city centre (http://www.radissonblu.co.uk/
In addition to his experience in the hotel industry, Christopher holds a Diploma as Chef from the Bournemouth and Poole College of Further Education in the UK. Acclaimed as a young chef, Christopher won the regional and national Junior Chaîne Des Rôtisseurs Competition, and represented South Africa in the World Finals in Germany. Among his many additional professional qualifications, Christopher holds a Master in Food Services Management from Cornell University. Though Christopher is filling a management role, and not working as part of the hotel's food service team, his experience in this field will undoubtedly help him in his position as General Manager.
About Radisson Blu Hotels & Resorts:
Radisson Blu Hotels & Resorts (formerly Radisson SAS Hotels & Resorts), part of The Rezidor Hotel Group, offers first class service, providing guests with a contemporary, upscale hospitality experience. Radisson Blu has received numerous awards for Best Hotel Chain and is renowned for its "Yes I Can!" spirit of service and the "100% Guest Satisfaction Guarantee". September 2005 saw the roll out of a free broadband service across the portfolio - the first international hotel chain to offer this service. Radisson Blu currently includes almost 250 hotels either in operation or under development and more than 58,000 rooms in Europe (Bristol accommodation (http://www.radissonblu.co.uk/
For more information, visit www.radissonblu.co.uk.
PR Contact:
Karen Tew
Director of Sales & Marketing
Broad Quay
44 1179 458 508
Account Email Address Account Phone Number Disclaimer Report Abuse


text:
Train Angers → SaumurFrom € 9
Find a Train Ticket
Overview The average travel time between Angers and Saumur is 25 minutes. The quickest route is 20 minutes. The first train leaving Angers is at 05:32, the last at 22:57. There is an average of 12 trains a day between Angers and Saumur, leaving approximately every 56 minutes.
- Departure station : Angers st laud ( )
Why choose us?
3 million travellers in 2014
15,000 destinations
Rail Europe Travel+
Secured payment
Need assistance?
Travel forum
Travel resources
Contact Us
Main stations in Angers and Saumur
Departure station
Travel inspiration in Angers and Saumur


text:
© 2016 Need Supply CompanyAll Rights Reserved
Free Shipping & Returns
Orders Over $75 See Details
From Matteo, a supersoft queen-size linen pillowcase in White. Tonal stitching with quarter-inch finished hem at opening. Garment-washed for a softer hand. Made in U.S.A. with imported materials.
• 100% linen
• Machine wash cold, tumble dry low
• Made in U.S.A.
View Size Chart
20" length
33" width
View Size Chart
Free Shipping & ReturnsOrders Over $75
Sign up and get 10% off your next order.
© 2016 Need Supply Company—All Rights Reserved
Sign up for our newsletter and get 10% off your next order. Pretty sweet, we know.


text:
realmagick.com The shrine of knowledge.
Juan Corona
A selection of articles related to juan corona.
Original articles from our library related to the Juan Corona. See Table of Contents for further available material (downloadable resources) on Juan Corona.
- An Overview of Core Shamanism
- Core shamanism developed out of research done by Dr. Michael Harner. He discovered that all over the world, while the overall approaches to shamanism may be different, there were key elements in common. Dr. Harner then set about synthesizing these elements so...
Religions >> Native American, Shamanism
- Quartz (Rock Crystal)
- Receptive/Projective. All elements. Clear, many forms and colors! Probably the most versatile multi-purpose healing stone. Easy to cleanse, store info/energy in, program or amplify energy and healing with. Can both draw and send energy. Powerful clear ones...
Earth Mysteries >> Stones, Minerals & Metals
- Infinity
- Federico Fellini once said: "There is no beginning, there is no end, there is only the infinite passion of life." Infinity is the forever expanding heartbeat of the universe. A well-known symbol for this concept is the snake biting his own tail, or...
Mystic Sciences >> Symbology
Juan Corona is described in multiple online sources, as addition to our editors' articles, see section below for printable documents, Juan Corona books and related discussion.
Suggested News Resources
- MOUNTAIN BIKING: Fast starts key to victory at Vail Lake for Johnson, Gibson
- Especially Johnson, the uber-skilled independent rider from Laguna Hills, who covered the four-lap, 22-mile challenging course in 1 hour, 15 minutes, 31.22 seconds, nearly two minutes ahead of Rodgers of San Juan Hills. Temecula Great ...
- Basketball: Southern California and Northern California Regional scores and
- San Juan Capistrano Saddleback Valley Christian 68, La Canada Flintridge Prep 52. Regional semifinals, Tuesday, 7 p.m.
- Basketball: Friday's Open Division scores and updated Regional pairings
- #7 San Juan Capistrano Saddleback Valley Christian vs. #2 La Canada Flintridge Prep at La Canada St. Francis, 7:30 p.
- LIGA MX CLAUSURA Match Day 10 roundup
- Santos Laguna scored three early goals and held on for a 3-2 win over Pachuca Friday at Estadio TSM Corona. Martin Bravo opened the scoring in the 21st ... Juan Cuevas assisted on the capper with a header.
- IndyCar Series starts 2016 season on streets of St. Petersburg
- Juan Pablo Montoya, who drives for Team Penske, is the defending race champion. He was in title contention until the season finale at Sonoma, when Scott ... of Canyon Country, Rick Hendrik of Palmdale and Bill Badger of Santa Clarita.
Great care has been taken to prepare the information on this page. Elements of the content come from factual and lexical knowledge databases, realmagick.com library and third-party sources. We appreciate your suggestions and comments on further improvements of the site.
Juan Corona Topics
Related searchesarticuno name origin
joe thomas
kangaroo kangaroo culling
behaviorism definition
revolver loading and unloading
azcapotzalco the porfirian era
bernoullis equation
About - Contact - Advertising
© 2000 - 2016 Realmagick.com, All Rights Reserved.
© 2000 - 2016 Realmagick.com, All Rights Reserved.


text:
You have Adblock enabled. Adblock has been known to cause issues with site functionality. If you experience any difficulties, please try disabling Adblock. Close
Add to Favorite List:
Create a new folder:
Next »
Busty Ashley Robbins outdoor dildo masturbation
Recognize a pornstar in this video?
Help make pornstars easier to find on Tube8 by telling us who is in this video.
Thanks! The pornstar names will be added to this video when enough users submit the same names.
You must enter a pornstar name that already exists in our database.
- Category: Erotic
- Views: 227,331
- Added: 6 years ago
- Description: Big tits czech pornstar Ashely Robbins masturbating with dildo publibly outdoor
- Tags: nasty, masturbation, ashley, czech, outdoor
- Pornstars: Add Pornstar
- Favorite by: 247
- Featured: 6 years ago
- Report This Video
Video Comments
All Video Comments (3)


text:
And this is my masterpiece up to this point! 3 tiers of topsy turvy and bright colors. Fondant frosting and decor, with fondant stars shooting out of the top.
CakeCentral.com is the world's largest cake community for cake decorating professionals and enthusiasts.
(if this is a private computer)
Yes please, register now!


text:
Cold sores are caused by the herpes simplex virus. Herpes simplex virus type I is the one that usually causes a cold sore. Herpes simplex type II usually causes genital herpes. Either type can cause a lesion on the face or genitals. Most people are exposed to the virus as a child, but anyone can be exposed at any age. Once exposed, the virus lies dormant in the nerve cells of the skin and may reoccur as an active infection at or near the site where the first cold sore appeared.
Stress, illness, menstruation, fever and sun exposure may trigger the recurrence of a cold sore. Some seem to have recurrent outbreaks and are not aware of the triggers that cause the cold sore.
When a cold sore starts, the area usually has an itching or tingling sensation, called prodome. This usually occurs one to two days prior to the blister forming. The usual duration is seven to ten days. First a blister forms, breaks and oozes. A yellow crust forms and sloughs off to pink skin that heals with no scar.
The incubation time for a cold sore after exposure is up to 20days. This delayed reaction usually causes the person to forget that they were exposed. It is possible that you may not know you are exposed at all. It is best to avoid sharing any lip balm or lipstick to avoid spreading the virus. Kissing someone with a cold sore is also contagious as well as sharing drinks, food utensils, towels or razors.
Canker sores are sometimes thought of as a cold sore, but is totally different. A canker sore is an ulceration in your mouth and is not contagious, A cold sore is caused from the herpes simplex virus and is very contagious.
Getting a prescription for an antiviral medication is the best way to shorten the duration and pain of the cold sore. If started at the first sign of the cold sore, the medication can alleviate most of your symptoms. Without any treatment, the discomfort may last up to ten days. If a prescription can't be obtained, there are several over the counter medications to help, but will not alleviate the cold sore. Over the counter medications will help ease the discomfort, but not shorten the duration. It is always best to visit your physician for treatment. This can alleviate a lot of the pain, discomfort, and embarrassment of having these lesions.
You May Also Like
Cause of a Cold Sore
Cold sores begin as a numb or tingly spot on the lip or nose, and quickly progress to become painful oozing blisters....
How to Treat Cold Sores on Lips
Apply a small amount of the cold sore treatment directly onto the cold sores on your lips and the surrounding area. ......
What Causes Cold Sore Flare-Ups?
Also called a fever blister, a cold sore is a lesion -- generally appearing on the lips -- caused by a virus...
Inside Lip Canker Sore Treatment
Inside Lip Canker Sore Treatment. ... Canker sores can cause severe pain and discomfort for several days, but they usually go away...


text:
The new home of
20 reviews
This good sized detached stone cottage with beautiful large multi-tiered garden and farmhouse-style kitchen, is located in Hayfield, a picturesque, historic village renowned for its high quality gourmet public houses and more recently as the set for BBC's popular drama 'The Village'. The village also has a fish and chip shop and a cafe. Right on the edge of the Peak District National Park, this holiday property is ideal for both walkers and cyclists alike, being situated at the foot of the Kinder Scout, a traditional starting point for the Pennine Way and Sett Valley Trail. Surrounded by outstanding scenery, Twenty Trees and Bluebell Wood Nature Reserves are right on the doorstep, and the famous market town of Chapel-en-le-Frith can be reached in 10 minutes. Lyme Park, the Hope Valley and caves of Castleton, and the spa town of Buxton with its famous opera house, museums and shops are just 20 minutes away, and the hugely popular market town of Bakewell, famous for its puddings, can be easily reached within 40 minutes. The magnificent historic houses of Chatsworth Estate and Haddon Hall are both easily accessible, and more locally, Hayfield itself even hosts its own annual events including the popular country show and sheepdog trials, well dressing and carnival 'May Queen' and the three day music festival, Hayfest. Shop 250 yards, pub serving food 300 yards.
Lower ground floor: Dining room/kitchen. 1 twin bedroom with two additional singles. Bathroom with shower over bath and toilet. All rooms with beams. Some rooms with tiled floor. Ground floor: Living room with beams and wooden floor. 1 double (5ft) bedroom. Open sided stairs to first floor: 2 bedrooms: 1 double (6ft), 1 twin. Shower room with toilet.
Open fire on landing area and woodburner in living room (initial fuel included). Gas central heating, gas, electricity, bed linen and towels included. Travel cot and high chair on request. Freeview TV. DVD. Wii. CD. Gas cooker. Microwave. Washing machine. Dishwasher. Fridge/freezer. Wi-fi. Large enclosed lawned multi-level garden with sitting-out area and furniture. Parking (1 car). Welcome pack. No smoking. NB: Sloping banks and pond in garden.
Looking for something with a little more?
cottages.com is a trading name of Wyndham Vacation Rentals (UK) Ltd. Registered in England and Wales.
Registered Office: Spring Mill, Stoney Bank Road, Earby, Lancashire,BB94 0AA, UK
Company Registration Number 00965389. VAT Registration Number: GB 598 22 99 77
Subscribe to our latest Deals & offers
cottages.com is the new home of cottages4you (Cottages for You).
cottages.com is a trading name of Wyndham Vacation Rentals (UK) Ltd. Registered in England and Wales.
Registered Office: Spring Mill, Stoney Bank Road, Earby, Lancashire,BB94 0AA, UK
Company Registration Number 00965389. VAT Registration Number: GB 598 22 99 77


text:
Tubing Half-Teaser
The Tubing Half-Teaser exercise works your abs.
-Flat Abs Fast. Tubing Half-Teaser: The trick here is to roll your torso off the floor using your abs and not pulling up with your arms. Try drawing your navel into your spine. You're gonna do 8 reps on this leg, then switch legs and repeat.


text:
Few days ago I fitted the Quaiffe ATB Differential in my car. I fitted in a Opel service dealer and I gave them 170 euro ~120 GPB for working&parts must needed change. I don't know if I payed expensive.
So, now I am from the lucky guys who have a differential like this in our cars.
My problem is the above..
My car is about standard around 150-155bhp.
But it spins the wheels easy even with the ATB fitted & with second gear.
These it happens because in Greece the roads is like to drive to ice.
When I turn fast with a second gear and use more than half gas pedal the car wants to understeering. I discovery that if I turn more the wheels, the care close the circle and the understeerind is reduce. Sometimes the same it happens if you give some more in accelaration pedal. But if you put on the floor the accelaration pedal you have 100% understeering, because you loose the traction in both wheels. This it happens that I sayed again even with the second gear and in speeds around 40 mph with a standard c20xe engine. Before anyone says that I don't have good tyres, I have F1's with 205/45/16 diameter in good condition.
The problem is the roads.
Some of you have this differential or your cars.
I want to ask, what is the best way to drive fast a fwd car with a lsd diff,in the enter of the turn, inside the turn,when you go out of the turn, and what other you know when steering fast with a diff like this.
I know that with time I will make a practice of it, bit always some of you may know some more than me.


text:
The music was a hit in America. A patriotic song, "Adams and Liberty" (later changed to "Jefferson and Liberty"), adopted the tune, which was also used for a song celebrating the naval war against Barbary pirates, early in the 19th century: "When the warrior returns, from the battle afar, To the home and the country he nobly defended...." And who had written that? Francis Scott Key.
"The Star-Spangled Banner" was popular, but not our national anthem. Not until 1931 did Congress grant that status. Before that we'd made do with "My Country 'Tis Of Thee," our version of "God Save the King (Queen)" as an anthem. (Many people still regret that "America the Beautiful" wasn't chosen.) But Key's song, played more slowly than the original song, with a few crashing chords and drumrolls, works well because it deals with our flag. We Americans don't have a king or queen. We have a flag.
The Smithsonian got this one in 1907, as a loan from Armistead's grandson that turned into a gift. A strange red V may have been the start of an A for Armistead. Some missing pieces were probably snipped out for souvenirs. They were likely not shot away during the bombardment. In that rain, the flag would have drooped against its mast with little chance of being hit.
In fact, some experts believe that the giant Pickersgill flag wasn't raised at all until that clear morning when Key saw it; another banner had flown in the rain. The impact on Key as the morning breeze finally revealed the enormous emblem of his beloved country — beaten, scoffed at, but still in the fight — must have been explosive.
Even in these cynical days, Americans who have lived abroad for a while, and suddenly meet the Stars and Stripes, feel a wrenching emotional surge — the pulse quickens, breath shortens, the throat tightens. In Alice Duer Miller's narrative poem "The White Cliffs," an American girl, living in England during World War I, feels Britain's anger and dismay at our continued neutrality during three years of suffering. Then the American doughboys arrive on their way to the trenches:
Marching through London to the beat of a boastful air,
Seeing for the first time Piccadilly and Leicester Square,
All the bands playing: "Over There, Over There,
Send the word, send the word to beware - "
And as the American flag went fluttering by,
Englishmen uncovered, and I began to cry.
By Edwards Park